Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.41 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.41 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.41 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | CHRM2 | P08172 | 3/20 | 0.37 |
| ▸ | CHRM4 | P08173 | 3/20 | 0.37 |
| ▸ | CHRM5 | P08912 | 3/20 | 0.37 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.37 |
| ▸ | CHRM3 | P20309 | 3/20 | 0.37 |
| ▸ | CCR5 | P51681 | 1/20 | 0.36 |
| ▸ | PRCP | P42785 | 1/20 | 0.36 |
| ▸ | TACR1 | P25103 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1030140 | 0.86 | KMT2A (0.40) | KMT2ATDP1OPRK1OPRM1OPRD1 | |
| SCHEMBL944256 | 0.86 | TDP1 (0.41) | KMT2ATDP1OPRK1OPRM1OPRD1 | |
| SCHEMBL1030142 | 0.86 | KMT2A (0.40) | KMT2ATDP1OPRK1OPRM1OPRD1 | |
| SCHEMBL943362 | 0.84 | KMT2A (0.39) | KMT2ATDP1OPRK1OPRM1OPRD1 | |
| SCHEMBL1081090 | 0.84 | KMT2A (0.39) | KMT2ATDP1OPRK1OPRM1OPRD1 | |
| SCHEMBL2703180 | 0.82 | OPRK1 (0.43) | KMT2ATDP1OPRK1OPRM1OPRD1 | |
| SCHEMBL943677 | 0.82 | OPRK1 (0.43) | KMT2ATDP1OPRK1OPRM1OPRD1 | |
| SCHEMBL1075333 | 0.82 | OPRK1 (0.43) | KMT2ATDP1OPRK1OPRM1OPRD1 | |
| SCHEMBL943238 | 0.82 | ALDH1A1 (0.44) | KMT2AALDH1A1CCR5 | |
| SCHEMBL13472056 | 0.82 | XIAP (0.40) | KMT2ATDP1OPRK1OPRM1OPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2448935-B1 | SUBSTITUTED 2-CARBOXAMIDE CYCLOAMINO UREAS | NOVARTIS AG (CH) | 2015-06-24 | — | — | EP | disclosed |
| EP-2448946-B1 | 2-CARBOXAMIDE CYCLOAMINO UREAS USEFUL AS PI3K INHIBITORS | NOVARTIS AG (CH) | 2013-07-24 | — | — | EP | disclosed |
| US-8357707-B2 | 2-carboxamide cycloamino ureas | NOVARTIS AG (CH) | 2013-01-22 | — | — | US | disclosed |
| US-8357707-B2 | 2-carboxamide cycloamino ureas | NOVARTIS AG (CH) | 2013-01-22 | — | — | US | disclosed |
| US-8357707-B2 | 2-carboxamide cycloamino ureas | NOVARTIS AG (CH) | 2013-01-22 | — | — | US | disclosed |
| US-8293753-B2 | Substituted 2-carboxamide cycloamino ureas | NOVARTIS AG (CH) | 2012-10-23 | — | — | US | disclosed |
| US-8293753-B2 | Substituted 2-carboxamide cycloamino ureas | NOVARTIS AG (CH) | 2012-10-23 | — | — | US | disclosed |
| US-8293753-B2 | Substituted 2-carboxamide cycloamino ureas | NOVARTIS AG (CH) | 2012-10-23 | — | — | US | disclosed |
| US-20110003786-A1 | 2-Carboxamide Cycloamino Ureas | NOVARTIS AG | 2011-01-06 | — | — | US | disclosed |
| US-20110003818-A1 | Substituted 2-Carboxamide Cycloamino Ureas | NOVARTIS AG (CH) | 2011-01-06 | — | — | US | disclosed |
| US-20110003818-A1 | Substituted 2-Carboxamide Cycloamino Ureas | NOVARTIS AG (CH) | 2011-01-06 | — | — | US | disclosed |
| US-20110003786-A1 | 2-Carboxamide Cycloamino Ureas | NOVARTIS AG | 2011-01-06 | — | — | US | disclosed |
| US-20110003786-A1 | 2-Carboxamide Cycloamino Ureas | NOVARTIS AG | 2011-01-06 | — | — | US | disclosed |
| US-20110003818-A1 | Substituted 2-Carboxamide Cycloamino Ureas | NOVARTIS AG (CH) | 2011-01-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110003786-A1 | 2-Carboxamide Cycloamino Ureas | PIK3C3, PRKACA, UACA | KMT2A 2205/4885TDP1 2390/4885OPRK1 2930/4885 |
| US-20110003818-A1 | Substituted 2-Carboxamide Cycloamino Ureas | UCK2, ULK3, ULK2 | KMT2A 1889/4885TDP1 2538/4885OPRK1 948/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.